In the TOGETHER-PsO trial, 27% of patients on ixekizumab plus tirzepatide achieved complete skin clearance and at least 10% weight loss at 36 weeks.
2
The combination therapy met the primary endpoint, showing superiority over ixekizumab monotherapy in achieving skin clearance and weight reduction.
3
A key secondary analysis revealed 41% of the combination group achieved Psoriasis Area and Severity Index 100, a 40% relative increase over monotherapy.
4
The trial enrolled 274 adults with moderate-to-severe plaque psoriasis and obesity, with a mean BMI greater than 39 kg/m².
5
Adverse events from the combination therapy were mild to moderate, with nausea and diarrhea being the most reported side effects.
The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.
